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ABSTRACT 
Background: Various surgical approaches for the management of midline anterior 
skull base meningiomas exist in the literature. The main surgeon target is proper 
selection the appropriate approach that achieves total removal of the lesion without 
causing morbidity or mortality and facilitates safe effective removal of the tumor. 
Objectives: To evaluate the role of the extended pterional approach for excision of 
midline anterior skull base meningiomas as regard the effectiveness, extent of 
resection and surgical outcome. 
Patients and methods: This retrospective study involved 23 cases with midline 
anterior skull base meningiomas resected through the extended pterional approach. 
Patients' clinical data, operative notes, imaging studies and clinical follow-up data 
were analyzed and evaluated. 
Results: Tumors studied were 9 olfactory groove meningiomas, 8 tuberculum Sellae 
meningiomas, 4 planum sphenoidale meningiomas and 2 diaphragma sellae 
meningiomas. Gross total resection tumor excision in 15 cases (64.5%), subtotal 
excision in 5 cases (21.5%) and partial excision in 3 cases (14%). Complications were 
diabetes insipidus (2 cases 8.6%), CSF rhinorrhea (3 cases 12.9%) and visual 
deterioration (3 cases 12.9%). We had two cases of mortality. 
Conclusion: The extended pterional approach allows safe and effective removal of 
midline anterior skull base meningiomas. It expands the exposure offered by the 
classic pterional approach and minimizing the necessity for applying fixed brain 
retraction with good cosmetic outcome and less approach related morbidities in 
comparison with the extensive skull base approaches. 
 
 
INTRODUCTION 
Pituitary adenomas are relatively common brain tumor with benign 
features, and, in fact, they are found in 10%-17% of the general 
population. Surgical resection continues to be the preferred treatment 
except for prolactin-secreting tumors. The nature of the pituitary 
adenoma itself suggests the possibility of tumor recurrence, 
regardless of its endocrinological characteristics. Recurrence rate 
Keywords 
extended pterional, 
meningioma, 
skull base, 
extent of resection  
 
 
 
 
Corresponding author: 
Mahmoud Saad Mohamed 
 
Neurosurgery Department, 
Mansoura Collage of Medicine, 
Mansoura University, Egypt 
 
dr_mhmodsaad@yahoo.com 
 
 
 
 
Copyright and usage. This is an Open Access 
article, distributed under the terms of the Creative 
Commons Attribution Non–Commercial No 
Derivatives License (https://creativecommons 
.org/licenses/by-nc-nd/4.0/) which permits non-
commercial re-use, distribution, and reproduction 
in any medium, provided the original work is 
unaltered and is properly cited. 
The written permission of the Romanian Society of 
Neurosurgery must be obtained for commercial 
re-use or in order to create a derivative work. 
 
 
ISSN online 2344-4959 
© Romanian Society of 
Neurosurgery 
 
 
 
First published 
March 2020 by 
London Academic Publishing 
www.lapub.co.uk 
 
 72 Ahmed Nageeb Mohamed Taha, Hosam Shata Mohamed, Mahmoud Saad Mohamed 
of pituitary adenoma after surgical resection has 
been reported up to 30%, and regrowth after 
incomplete tumor removal was reported in up to 
75% of cases (2,5,10,12,16). 
Recurrent tumors can be managed with 
observation, medical therapy, radiotherapy, 
radiosurgery, or revision surgery. Additionally, the 
combined treatment paradigm is essential in some 
cases because all treatment modalities have 
advantages and disadvantages. Surgery for a 
recurrent lesion is burdened by increased risk of 
mortality and morbidity, and it often results in 
incomplete resection compared with initial surgery. 
Radiosurgery and stereotactic radiotherapy can be 
recommended as adjuvant treatments to obtain 
long-term control with low procedure-related 
morbidity in selective cases. However, the repeated 
surgical resection is crucial in cases of sizable 
adenomas compressing the optic apparatus, or 
hormone-secreting adenomas (1,2,3,4,7,9,14). 
Nearly a century ago, Harvey Cushing realized the 
limitations of microsurgical approaches for treating 
pituitary adenomas. Cushing and his colleagues used 
a radium bomb to deliver a single-session, focused 
radiation to treat pituitary adenomas. Henceforth, 
neurosurgeons and radiation oncologists have 
employed repeat resection or ionizing radiation to 
treat selected patients with recurrent or residual 
pituitary adenomas(1,6,22,24). 
During the last century, pituitary surgery has 
been developed with various technical modifications 
and instrumental advances, and the outcome has 
been generally excellent, with high rates of clinical 
improvement and endocrinological remission and 
minimal rates of morbidity and mortality. The 
introduction of endoscopy in the transsphenoidal 
approach (TSA) has tremendously advanced the 
midline skull base surgery. In the literatures, the 
efficacy and safety of endoscopic TSA in the 
management of pituitary adenomas have been 
proven and the complication rates of endoscopic TSA 
are at least comparable with those of microscopic 
series. However, the reports on endoscopic TSA as a 
revision surgery have been less commonly published 
(6,8,11,13,15,19,26,28). 
We retrospectively evaluated the efficacy and 
safety of the endoscopic TSA for recurrent pituitary 
adenomas as regard extent of resection, ICA injury 
and CSF leakage and related reconstruction 
obstacles. 
MATERIAL AND METHODS 
A retrospective study is conducted on 30 patients 
with recurrent pituitary adenomas that were re-
operated up on via endoscopic endonasal 
transsphenoidal approach at the Neurosurgery 
Department, Mansoura University over the period 
from 2013 to 2019. Patients who did a previous 
transsphenoid either via microscopic or endoscopic 
technique are included in the study. The indications 
to do another endoscopic endonasal 
transsphenoidal approach were big residual or 
recurrent tumor compressing the chiasm, persistent 
endocrinological problem due to residual adenoma. 
Patient demographic and previous surgery data 
were collected and analyzed including any previous 
medical treatment, radiation treatment and any 
previous surgery related morbidities. Routine pre-
operative complete ophthalmological assessment 
was done for all cases and was repeated after 
surgery to assess the outcome. Pre- and 
postoperative endocrinological assessment were 
done for all cases including serum prolactin, free 
cortisol, ACTH, free thyroxine, TSH, GH and insulin-
like growth factor 1 (IGF-1). Serum electrolytes and 
fluid chart were done for all cases with diabetes 
insipidus that present either prior or after the 
surgery. Pre-operative contrast-enhanced MRI were 
done for all the patients and then 3 months after 
surgery and then yearly for follow up. The tumors 
were assessed regarding its size and extension. 
Tumor volumes were assessed by the ellipsoid 
model “(ABC)/2” equation. The degree of cavernous 
sinus invasion was evaluated based on Knosp 
criteria. The extent of tumor resection (EOR) was 
assessed based on a post-contrast MRI study done 3 
months after surgery.  
 
SURGICAL TECHNIQUE 
We utilize the standard endoscopic approach for 
pituitary adenoma surgery which is widely described 
in the literature, and we will stress on our steps in 
relation to surgery for recurrent cases. Lumbar drain 
was utilized for cases with history of previous CSF 
rhinorrhea with the initial surgery and for cases we 
have encountered intra-operative CSF leakage and 
was left for 1 to 3 postoperative days for 
postoperative drainage. The important steps to 
ensure efficient safe surgery for recurrent cases 
were binostril four handed endoscopic technique 
with wide sphenoidotomy and obtaining adequate 
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sellar exposure to have the full panoramic view ofthe 
carotid prominences, medial and lateral optico-
carotid recesses, planum and clivus. Our biggest 
challenge was the way to achieve adequate 
reconstruction after tumor resection. Options were 
reusing prior flap from the previous surgery, 
obtaining a contralateral nasoseptal flap but in many 
cases with extensive adhesions and disturbed 
normal anatomyespecially those previously 
irradiated;abdominal fat graft or fascia lata graft was 
utilized to achieve sellar reconstruction. 
 
RESULTS  
Thirty patients involved in this study were operated 
up on via endoscopic endonasal transsphenoidal 
surgery for recurrent or residual pituitary adenomas. 
18 were females and 12 were males. Age ranged 
from 29 to 61 years (mean 50 years). Twenty-four 
patients (80%) had single prior endoscopic 
endonasal transsphenoidal surgery. The remaining 6 
patients (20%) had 2 previous transsphenoidal 
surgeries. In 23 patients; the initial surgery was done 
at Neurosurgery Department, Mansoura University 
Hospitals while the remaining seven cases were 
previously operated up on in other hospitals. The 
initial surgery was done microscopically in 13 cases 
while the other 17 cases were operated up on via the 
endoscopic approach (table 1). 
The mean interval between the previous surgery 
and the redo endoscopic endonasal surgery was 30 
months (ranged from 19 months to 42 months). 19 
patients (63.3%) presented with tumor growth on 
follow up MRI brain before the onset of clinical 
symptoms andwere re-operated uponbecause of 
growth of the residual tumor or persistent 
symptoms related to a persistent hormone 
hypersecretion. In 11 patients (36.6%); the tumor 
recurred after previous total resection documented 
on postoperativeMRI brain. 21 patients (70%) had 
macro-adenomasat recurrence while the remaining 
nine patients (30%) had giant adenomas. 
The clinical presentation was visual affection in 9 
patients (30%), headache in 3 patients (10%), 
amenorrhea galactorrhea in 5 patients(16.6%)and 
persistent acromegalic features in 8 patients 
(26.6%).Only 4 patients received adjuvant 
radiotherapy following first surgery (table 1).17 
patients (56.6%) had nonfunctional pituitary 
adenomas. 8 patients (26.6%) had GH adenomas and 
5 patients (16.6%) had a prolactinoma. Tumor 
locations varies at time of presentation and 
determined radiologically with contrast enhanced 
MRI brain and distributed into: confined to sella in 7 
cases (23.3%), sellarwithsuprasellar extension in 12 
cases (40%), sellar with parasellarextension in 6cases 
(20%) and sellar, suprasellar and parasellar 
extension in 5 cases (16.6%) (table 2). 
Overall Gross total resection was achieved in 17 
patients (56.6%) while subtotal and partial resection 
in 13 patients (43.4%) confirmed by Gadolinium 
enhanced magnetic resonance imaging of the brain 
done 3 months after surgery (table 3). Total resection 
was achieved in 11 cases of non-functioning 
adenoma, 3 cases of growth hormone secreting 
adenomas and 3 cases of prolactinomas. Total 
resection was achieved in 9 (47.3%) residual 
adenomas and in 8 (72.7%) recurrent 
adenomas.According to the tumor extension; total 
resection was feasible in 5 out of 6(83.3%) cases 
where the tumor is confined to sellae, in 10 out of 12 
(83.3%) cases where is tumor is sellar and suprasellar 
extension and in 1 out of 11 (9.09%) of cases that had 
parasellar extension into the cavernous sinus. 
Subtotal resection was done in 6 cases of non-
functioning adenoma, 5 cases of growth hormone 
secreting adenomas and 2 cases of prolactinomas. 
Subtotal resection was achieved in 10 (52.6%) 
residual adenomas and in 3 (27.2%) recurrent 
adenomas. According to the tumor extension; 
subtotal resection was done in 1 out of 6 (16.6%) 
cases where the tumor is confined to sellae, in 2 out 
of 12 (16.6%) cases where is tumor is sellar and 
suprasellar extension and in 10 out of 11 (90.9%) of 
cases that had parasellar extension into the 
cavernous sinus (table 3).  
No further treatment was required for the 17 
cases with total tumor resection. Among 6 cases of 
non-functioning adenoma with incomplete 
resection; 4 cases were done via microscopic 
transcranial approach and 2 of them offered 3-
dimensional radiotherapy after the transcranial 
surgery while the other 2 cases were treated with 
gamma knife radiosurgery. We have 5 cases of 
acromegaly with incomplete resection; one was 
offered additional microscopic transcranial 
approach followed by conformal radiotherapy, 3 
offered Gamma knife radiosurgery and one died 
from ruptured carotid pseudoaneurysm from intra-
operative vascular injury. 2 cases of residual 
prolactin secreting adenomas were treated 
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medically with dopamine agonists and one of them 
received conformal radiotherapy after failed trail of 
medical treatment.  
We have a case of mortality from carotid injury in 
a case of recurrent growth hormone secreting 
adenoma. 3 cases had post-operative CSF 
rhinorrhea; 2 passed conservatively and one 
required another endoscopic repair. 4 cases 
developed post-operative diabetes insipidus (2 
required permanent treatments). 3 cases developed 
post-operative hypopituitarism requiring long term 
hormonal replacement therapy. Improvement of the 
visual manifestations occurred in 5 (55.5%) out of the 
9 cases presented with visual affection regarding 
visual acuity and visual field disturbances (table 4). 
Regression of acromegalic features and 
normalization of growth hormone and insulin-like 
growth factor occurred in 3 (37.5%) out of 8 
acromegalic cases while the other 5 (62.5%) cases 
failed to improve necessitating further treatment to 
control endocrinological problem. Restoration of 
normal menstrual cycle and cessation of 
galactorrhea occurred in 3 cases after total tumor 
removal while the other 2 cases with residual tumor 
were kept on medical treatment and one case 
received radiotherapy. 
 
Table 1. Clinical and demographic distribution of recurrent 
adenoma patients 
 
ILLUSTRATED CASES 
Case 1: Forty-two years old male patient with 
recurrent non-functioning pituitary adenoma (fig. 1 a 
& b) with visual compression totally resected (fig. 1 c 
& d) with marvelous visual improvement. 
Case 2: Fifty-four years old female patient with 
recurrent growth hormone secreting adenoma with 
visual compression (fig. 2 a & b); subtotal resection 
due to cavernous sinus invasion with good optic 
apparatus decompression (fig. 2 c & d) and followed 
by Gamma knife radiosurgery. 
 
DISCUSSION 
Recurrent or residual pituitary adenomas after 
transsphenoid approach whether done 
microscopically or endoscopically represent a 
potential challenge in deciding the best appropriate 
treatment. Many options of treatment are available 
including just follow up, medical treatment for some 
functioning adenoma, radiotherapy including 
gamma knife, microscopic transcranial resection and 
repeat the transsphenoid approach. The decision is 
based up many factors including size of the residual 
or recurrent adenomas, pattern of the tumor 
extension, nature and function of the adenoma, 
clinical presentation and data regarding previous 
operation, surgery related morbidities and if any 
adjuvant treatment was given after the initial surgery 
(1,3,8,21,23,25,29). 
 
Feature Number (%) 
Gender: 
Male 12 (40%) 
Female 18 (60%) 
Pathology: 
Nonfunctioning 17 (56.6%) 
GH producing 8(26.6%) 
Prolactinoma 5 (16.6%) 
Number of previous surgeries: 
1 24 (80%) 
2 6 (20%) 
Previous resection: 
Recurrent tumor 11 (36.6%) 
Residual tumor 19 (63.3%) 
Clinical presentation: 
Tumor regrowth (MRI) 14 (46.6%) 
Visual 9(30%) 
Acromegaly 8 (26.6%) 
Headache 3 (10%) 
Amenorrhea galactorhea 5 (16.6%) 
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Tumor extension Total Residual 
adenoma 
Recurrent 
adenoma 
Sellar 7 2 5 
Sellar& suprasellar 12 6 6 
Sellar&parasellar 6 6 0 
Sellar&suprasellar& 
parasellar 
5 5 0 
 
Table 2. Pattern of tumor extension 
 
 
Extent of 
previous 
resection 
Number 
of cases 
Gross 
total 
resetion 
Tumor extension 
Residual 
tumor 
19 9 (30%) 2 sellar, 6 sellar & 
supra sellar, 1 
sellar &p arasellar 
Recurrent 
tumor 
11 8 (26.6%) 4 sellar, 4 sellar & 
suprasellar 
 
Table 3. Pattern of tumor extension Extent of tumor resection 
correlated to pattern of tumor extension 
 
 
Table 4. Outcome of surgery of recurrent pituitary adenomas 
correlated to literature reports 
In this study we evaluated our results of endoscopic 
transsphenoid approach for recurrent and residual 
pituitary adenomas. Among the 30 cases involved in 
this study; 19 cases were residual tumors and 11 
cases were recurrent after initial total resection. 
Among the 19 cases with residual tumors; 11 (57.9%) 
cases had tumor extension to the cavernous sinus 
and this reflects that the extent of tumor resection 
was more related to the pattern of tumor extension 
rather than the nature of the adenoma or the 
technique of surgery whether microscopic or 
endoscopic. In 8 patients with residual adenomas; 
the tumor was confined to sella in 2 cases and sellar 
with suprasellar extension in 6 cases and the reason 
for incomplete tumor removal was inadequate 
opening all the sphenoid septationswith limited 
delineation of the sellar floor with less room for 
manipulating the endoscope and the instrument.  
 
 
series No. of 
cases 
EOR (No. of cases, 
%) 
No. of cases, % of cases Other 
complications 
GTR STR Complications Hypopit. DI CSF leak 
Curent 
study  
30 17, 
56.6% 
13, 
43.4% 
8, 26.6% 0 4, 13.3% 3, 10% Mortality: 1 (carotid 
injury) 
Negm et al. 
2017 
41 24, 
55.5% 
2, 4.9% 8, 19.5% 4, 9.7% 2, 4.9% 1, 2.4% Hematoma: 1 (2.4%) 
Wang et al. 
2015 
29 16, 55% 11, 38% 5, 17% 0 1, 3.4% 1, 3.4% 2 (6.9%) cases of 
deerioration of 
vision due to 
hemorrhage in 
tumor bed & 
intracranially; 6th 
nerve palsy: 1 (3.4%) 
Tajudeen et 
al. 2015 
27 17, 63% 7, 26% 6, 22% 1, 3.7% 2, 7.4% 0 Abducent palsy: 1 
(3.7%) 
Cavallo et 
al. 2012 
59 37, 63% 9, 15% 8, 13.5% 4, 6.7% 3 (5%) 1 
(1.7%)† 
Hematoma: 1 (1.7%) 
Rudnik et 
al. 2006 
20 8, 40% 0 4, 20% 3, 15% 0 1, 5%  
Hwang et 
al. 2013 
30 15, 50% 7, 23% 5, 16% 1, 3.3% 4 (13.3%) 0 Mengitis: 2 (6.7%) 
Yamada et 
al. 2010 
53 31, 
58.5% 
0 5, 9% 1, 2% 1, 2% 1, 2% Epistaxis: 1 (2%), 
pituitary abscess: 1 
(2%) 
Alahmadi 
et al. 2011 
39 18, 46% 21, 54% 6, 13% 0 0 1 
(2.6%)† 
1 MI, 1 HCP, 1 
sinusitis, 1 crushing 
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Mattozo et 
al. 2006 
30 17, 57% 0 5, 17% Hypoth: 
1, 3.3% 
1, 3.3% 1, 3.3% Sinusitis: 1 (3.3%), 
hyponatremia: 1 
(3.3%) 
Benveniste 
et al. 2005 
96 0 0 29, 30% 15, 15.6% 5, 5.2% 1, 1% CN palsy: 1, graft site 
infection: 1, sinusitis: 
5, epistaxis: 1 
 
CN = cranial nerve; HCP = hydrocephalus; Hypopit = hypopituitarism; Hypoth = hypothyroidism; MI = myocardial infarction; PE = 
pulmonaryembolism. 
* Represents a case of hypocortisolemia. 
† Patient also had meningitis. 
 
The importantsurgical step to facilitate efficient 
tumor resection was the use of binostril four handed 
endoscopic technique with wide sphenoidotomy and 
obtaining adequate sellar exposure to have the full 
panoramic view ofthe carotid prominences, medial 
and lateral optico-carotid recesses, planum and 
clivus. With this technique we achieved total 
resection of the all 8 cases with residual adenomas 
and 8 out of 11 recurrent cases involving the sellar 
and suprasellar area (2, 4, 9,18,20,24,27,29). 
Extensive tumor extension into the cavernous 
sinus is a barrier against total resection of pituitary 
adenoma disregarding the nature of the adenoma 
and whether it is de novo or recurrent. Some 
pituitary adenomas like growth hormone secreting 
adenomas had aggressive inherent biology enabling 
them to more easily invade surrounding dural 
and/or bony structures with early parasellar 
extension into cavernous sinus. The challenge of 
surgery inside the cavernous sinus increase 
markedly in recurrent cases particularly if the tumor 
is fibrous or if the patient was given radiation after 
the initial surgery. Aggressive attempts of tumor 
resection inside the cavernous sinus is hazardous 
and increase the potential surgical risks of vascular 
injuries and ocular cranial nerves palsy. Among the 
19 cases with residual tumors; 11 (57.9%) cases had 
tumor extension to the cavernous sinus and from 
the 11 cases with residual tumor in the cavernous 
sinus; we were able to achieve total tumor resection 
in one case at the 2nd surgery and in 10 cases; a 
residual tumor was left in the cavernous sinus for 
further adjuvant treatment and the reason for doing 
the redo surgery was that the tumor growth after the 
initial surgery and reduction of the tumor size has 
the advantage of reducing the mass effect to 
improve the visual manifestation, better achieving 
hormonal control in functioning adenomas and 
would improve the response and reduce the 
associated morbidities of subsequent adjuvant 
treatment(1,2,4,5,7,8,17,21,28). 
The extent of tumor resection for recurrent 
adenomas is addressed in many studies in the 
literature and the growth total resection could be 
achieved endoscopically in 40% to 63%. The studies 
of microscopic resection of recurrent pituitary 
adenomas had similar results with chance of total 
adenoma resection up to 60%. Although the 
similarity of the results in the literature; we did all the 
recurrent cases endoscopically as the we had 19 
cases (63.3%) of residual tumor that kept growing 
after the initial surgery and in 11 of them (57.9%); the 
residual tumor was in the parasellar region which is 
a hidden location for the microscopic view. 
Moreover, the extended endoscopic trans-
sphenoidal approach allowed better visualization 
and hence removal of the sellar and suprasellar 
component of the tumor than what could be done 
microscopically. Regardless of the better 
visualization and tumor manipulation, cavernous 
sinus invasion remained our greatest limiting factor. 
The overall Gross total resection in our study was 
achieved in 17 patients (56.6%) while subtotal and 
partial resection in 13 patients (43.4%) which is 
similar to what achieved in other reports in the 
literature (3,4,6,11,13,14,15,18,20,22,26,27). 
Reoperations on any recurrent tumor had a 
higher incidence of complication in comparison for 
operating a newly developed tumor. Rates of 
complications for recurrent pituitary tumors in many 
studies the literature ranged from 9.4% to 31.3%. 
Presence of scars and adhesions interfere with 
natural dissection plans adding difficulties for 
surgery. The challenge is valid for reoperation on 
recurrent adenomas with higher incidence of 
morbidities. One critical complication is the 
occurrence of CSF rhinorrhea after surgery. 
Intraoperative CSF leakage could be encountered 
easily because of scaring of the initial surgery and 
easily injuring the arachnoid during tumor 
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dissection. Multilayer reconstruction is crucial and if 
vascularized flaps could be obtained during the redo 
surgery; it was the best to prevent post-operative CSF 
leakage. In cases we were not able to harvest 
vascularized flap; we obtained fascialata and fat graft 
with fibrin glue to do solid reconstruction when we 
faced intra-operative CSF leakage. Then lumbar drain 
was left up to 3 days after surgery. Despite our 
aggressive reconstruction plan; 3 cases had post-
operative CSF rhinorrhea; 2 passed conservatively 
and one required another endoscopic repair. The 
incidence of post-operative pituitary hormonal 
insufficiency was slightly higher with surgery for 
recurrent adenomas. A meta-analysis of the result 
endoscopic surgery for recurrent adenomas 
reported transient DI in 7%, permanent DI in 2.5%, 
and anterior pituitary hormonal insufficiency in 1.5%. 
We had 2 cases (6.6%) of transient DI, 2 cases (6.6%) 
of permanent DI, 3 cases (10%) developed post-
operative hypopituitarism requiring long term 
hormonal replacement therapy. We had a case of 
mortality from vascular injury during doing a case of 
recurrent growth hormone secreting adenomas 
(1,7,8,10,16,17,19,22,23,29). 
 
CONCLUSIONS 
Endoscopic endonasal approach for recurrent or 
residual pituitary adenomas allows optimum 
visualization and better delineation of all hidden 
corridors to achieve the safest maximum resection. 
Although cavernous sinus involvement still prevents 
total resection but aggressive safe tumor debulking 
is essential to reduce the compression 
manifestation, improve hormonal control and 
optimize the result of any further adjuvant treatment 
including radiotherapy or radiosurgery. Adequate 
endoscopic exposure is crucial to improve the extent 
of resection and minimize the potential morbidities. 
Solid reconstruction plan is very important to 
minimize post-operative CSF leakage.  
 
(a)          (b) 
 
 
(c)          (d) 
 
Figure 1. Preoperative MRI image of recurrent nonfunctioning 
pituitary adenoma sagittal view (a), axial view (b), postoperative 
follow-up MRI images sagittal view (c), axial view (d). 
 
 
 
 
 
 
 
 
 
 
 
(a)         (b) 
(c)         (d) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Preoperative MRI image of recurrent growth 
hormone secreating adenoma sagittal view (a), axial view (b), 
postoperative follow-up MRI images sagittal view (c), axial view 
(d). 
 
ABBREVIATIONS  
EOR=extent of resection, COZ= cranio-orbito-zygomatic, ICT= 
intracranial tension, CSF= cerebrospinal fluid, OGM= olfactory 
groove meningioma, GTR= gross total resection, STR= subtotal 
resection, TSM= tuberculum sellae meningioma, PSM= planum 
sphenoidale meningioma.  
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